Clinical trials: Biological Availability
Healthy
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins.
- Trial name
- NCT03053622
- Testing
- Mirikizumab Test, Mirikizumab Reference
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of of Olodaterol and Ketoconazole
This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
- Trial name
- NCT01153711
- Testing
- BI 1744, Ketoconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Non-smoker
Matrix on Fruit Constituent Bioavailability
Primary objective is to evaluate the influence of matrix on the bioavailability of key phytochemical constituents in fruits and their subsequent effect on chronic disease risk factors.
- Trial name
- FRT (NCT01908634)
- Testing
- Milk-based Strawberry Beverage without meal, Water-Based Strawberry Beverage without meal, Milk-based strawberry Beverage with meal
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two…
- Trial name
- NCT02648438
- Testing
- AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study of Dulaglutide in Healthy Participants
The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe.
- Trial name
- NCT03363906
- Testing
- Dulaglutide (Reference), Dulaglutide (Test)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteer
A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
This is a Phase 1, single-center, open-label, randomized, 3-period, 2-sequence crossover study of cobimetinib in healthy participants to evaluate the effect of the proton-pump inhibitor (PPI) rabeprazole on the relative…
- Trial name
- NCT01277718
- Testing
- Cobimetinib, Rabeprazole
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA…
- Trial name
- NCT00835497
- Testing
- 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
The main objectives of this trial are: To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to…
- Trial name
- NCT06520553
- Testing
- BI 1569912 (C-14), BI 1569912 (C-13)
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bioequivalence
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable…
- Trial name
- NCT01340625
- Testing
- Norethindrone/Ethinyl Estradiol, Ovcon® 35 Fe
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Human Immunodeficiency Virus-1 (HIV-1)
Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)
This study aims to evaluate and compare the relative bioavailability of different doravirine (MK-1439) experimental nano formulations (NFs) with that of a doravirine film coated tablet.
- Trial name
- NCT02549040
- Testing
- Treatment A: Doravirine 100 mg film coated tablet, Treatment B: Doravirine 150 mg tablet (40% drug loaded granule), Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bioavailability
Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.
- Trial name
- NCT02557139
- Testing
- Belumosudil Tablet, Belumosudil Capsule
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Kadmon Corporation, LLC
Healthy
A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood
The main objective of Trial Parts 1 and 2 is to investigate the relative bioavailability of two tablet strengths (low dose and high dose) of the intended Commercial Formulation of BI 730357 (Test, T) versus with the corresponding…
- Trial name
- NCT03886272
- Testing
- BI 730357 (Test), BI 730357 (Reference)
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations
- Trial name
- ERBA (NCT05446142)
- Testing
- Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove…
- Trial name
- NCT04548219
- Testing
- Mirikizumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Epilepsy, Seizures
Determination of Absorption and Elimination of Lamotrigine-XR
People over 65 years of ag break down (metabolize) drugs differently than younger adults. It is not known why this happens or how elderly people absorb or break down these drug differently.
- Conditions
- Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
- Trial name
- NCT00789113
- Testing
- Extended Release Lamotrigine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Healthy
Leflunomide 20 mg Tablets Under Fasting Conditions
This study will compare the relative bioavailability (rate and extent of absorption) of 20 mg Leflunomide Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 20 mg ARAVA™ Tablets by Aventis Pharmaceuticals, Inc.
- Trial name
- NCT00834418
- Testing
- Leflunomide 20 mg Tablets, ARAVA™ 20 mg Tablets
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy Participants
A Study of LY2940680 in Healthy Participants
This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants.
- Trial name
- NCT01681186
- Testing
- LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
The Purpose of this study is to assess the relative bioavailability, dose proportionality, the impact of food on the rate and extent of absorption, palatability of the selected pediatric formulation of maribavir and the safety…
- Trial name
- NCT04131556
- Testing
- Maribavir
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy
Pharmacokinetics of Lidocaine in Healthy Adults
The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Lidoderm® topical patch (manufactured by Endo…
- Trial name
- NCT03310970
- Testing
- Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Nicole K Brogden
Diabetes Mellitus, Type 2
A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants
This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh and arm.
- Trial name
- NCT03232983
- Testing
- LY900014 (SC), LY900014 (IV)
- Where
- Singapore
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company